Videos

Lidia, who was diagnosed with stage 4 lung cancer in 2016, offers her advice for others who have received a cancer diagnosis.

“There’s a lot of work to do in CLL,” said Dr. Mazyar Shadman about the treatments currently being investigated in CLL. “We have been very fortunate to be able to provide a lot of options to our patients, but we shouldn't forget that there's a long way to go.”

In an interview with CURE®, Dr. Mazyar Shadman discussed ways that patients with chronic lymphocytic leukemia can play a role in ensuring that they are able to reap the benefits of treatment.

There are three things that should be considered when deciding what is the optimal treatment in the first line setting for patients with chronic lymphocytic leukemia (CLL), according to Dr. Mazyar Shadman.

In an interview with CURE®, Dr. Pail Paik of the Memorial Sloan Kettering Cancer Center discusses the FDA approval of Alunbrig for patients with ALK-positive metastatic non-small cell lung cancer.

In partnership with CURE®, Susan G. Komen Greater New York City hosts its 4th Annual Patient Navigation Town Hall "Empowering and Mobilizing Our Patient Navigation Workforce". Oncologists, community health workers and patient navigators will get together on June 23rd, via webinar, to discuss the impact of the COVID-19 pandemic on the cancer landscape and how professionals and patients can navigate the fallout moving forward.

“I think until you've been put in a position that I'm in, we sometimes tend to take our lives and time that we have for granted.”

“Everything is perspective. It's how you look at it.”

4 Chronic Lymphocytic Leukemia experts hosted a webinar, in partnership with CURE, addressing the latest and most important topics for patients with CLL.

First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy improves progression-free survival in patients with locally recurrent, inoperable or metastatic triple-negative breast cancer (mTNBC), according to data presented at the 2020 ASCO Virtual Scientific Program.

CURE hosted its third webinar on all the latest topics and trends for patients with lung cancer.

In an interview with CURE, Lutheran Medical Center oncology patient navigator Laurie Hatch explains the best ways for patients with cancer and survivors to restart their exercise routine and the best ways to get moving again and combat side effects from treatment like fatigue.

The phase 3 trial evaluating eprenetapopt plus Vidaza completed enrollment recently, and could lead to a new standard of care with positive results, according to Dr. Guillermo Garcia-Manero.

Dr. Caron A. Jacobson discusses the potential long-term impact of Yescarta for patients with relapsed or refractory indolent non-Hodgkin lymphoma and how it could turn an incurable disease into something curable.

“Survivor: Africa” winner Ethan Zohn details his journey with cancer and discovering that it isn’t a sprint, but a marathon.

Rachel J. Wong, an oncology dietitian from Georgetown Lombardi Comprehensive Cancer Center, has some helpful tips on what patients and survivors can stock their pantry with to avoid stress eating and stay healthy through the pandemic and beyond.

Data presented at the ASCO 2020 Virtual Scientific Program demonstrated that Keytruda was an effective treatment for patients with Hodgkin Lymphoma and side effects were tolerable.

Being a young adult with cancer can feel like an isolating journey, but "Survivor: Africa" winner Ethan Zohn details how a community can form even in the unlikeliest of places.

The role of exercise in the cancer journey can provide its own form of medicine, explains one expert in an interview with CURE.

In an interview with CURE, “Survivor: Africa” winner Ethan Zohn talks about how his cancer journey changed his perspective on life and helps him to navigate the COVID-19 pandemic.

Dr. Nirav Niranjan Shah explains the data behind why autologous stem cell transplant should remain the standard of care for patients with relapsed chemo-sensitive DLBCL.

Former Survivor competitor, and winner, Ethan Zohn talks with CURE about his journey with cancer and raising awareness for patients with leukemia and lymphoma.

“This is the first randomized trial to demonstrate an overall survival benefit for patients with brain metastases, which I think is very significant,” said Dr. Nancy U. Lin.

While follow-up data on the BEACON CRC study demonstrated superior overall survival for certain patients with metastatic colorectal cancer receiving Braftovi, Mektovi and Erbitux, an exploratory analysis is needed to understand if this treatment can impact a wider subset of patients.

The HIF-2a Inhibitor induced clinical responses among patients with von Hippel-Lindau disease–associated kidney cancer, according to results presented at the 2020 ASCO Virtual Scientific Program.

“We now have second and third generation cousins of thalidomide that are very useful. So, lenalidomide in combination with rituximab is an effective therapy for mantle cell lymphoma that voids some of these adverse events that I’m talking about,” said Dr. Ian Flinn. Hear more about this treatment in his interview with CURE®.